**Author details**

Maria Maślińska\* and Brygida Kwiatkowska

\*Address all correspondence to: maslinskam@gmail.com

Early Arthritis Clinic, National Institute of Geriatrics, Rheumatology and Rehabilitation the name of Prof. Eleonora Reicher, Warsaw, Poland

## **References**


ed with human T-cell lymphotropic virus type 1. Am J Ophthalmol. 2006;142(5):811– 5.


in the Sjögren's International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken) 2012;64(4):475–87.


ed with human T-cell lymphotropic virus type 1. Am J Ophthalmol. 2006;142(5):811–

[8] Miceli-Richard C, Comets E, Loiseau P, Puechal X, Hachulla E, Mariette X. Associa‐ tion of an IRF5 gene functional polymorphism with Sjögren's syndrome. Arthritis

[9] Huang YF, Cheng Q, Jiang CM, et al. The immune factors involved in the pathogene‐ sis, diagnosis, and treatment of Sjogren's syndrome. Clin Dev Immunol. Vol.

[10] Baimpa E, Dahabreh IJ, Voulgarelis M, Moutsopoulos HM. Hematologic manifesta‐ tions and predictors of lymphoma development in primary Sjögren syndrome: clini‐

[11] Lemp MA. Report of the National Eye Institute/Industry Workshop on Clinical Trials

[12] Merayo-Lloves J, Baltatzis S, Foster CS. Epstein-Barr virus dacryoadenitis resulting in keratoconjunctivitis sicca in a child. Am J Ophthalmol. 2001;132(6):922–3.

[13] Rhem MN, Wilhelmus KR, Jones DB. Epstein-Barr virus dacryoadenitis. Am J Oph‐

[14] Bekele S, Gelaw Y, Tessema F. Ocular manifestation of HIV/AIDS and correlation with CD4+ cells count among adult HIV/AIDS patients in Jimma town, Ethiopia: a cross sectional study. BMC Ophthalmol. 2013;27;13:20. doi: 10.1186/1471-2415-13-20.

[15] Alves M, Angerami RN, Rocha EM. Dry eye disease caused by viral infection: re‐

[16] Krásny J, Hrubá D, Netuková M. The role of Chlamydia pneumoniae in the etiology of keratoconjunctivitis sicca (KCS). Recent Pat Inflamm Allergy Drug Discov.

[17] Hori Y1, Maeda N, Sakamoto M, Koh S, Inoue T, Tano Y. Bacteriologic profile of the conjunctiva in the patients with dry eye. Am J Ophthalmol. 2008 Nov;146(5):729-34.

[18] Faraj HG, Hoang-Xuan T. Chronic cicatrizing conjunctivitis. Curr Opin Ophthalmol.

[19] Rashida S, Danaa M. Cicatrizing and autoimmune diseases. Chem Immunol Allergy.

[20] Ormerod LD, Fong LP, Foster CS. Corneal infection in mucosal Scarring Disorders

[21] Shiboski SC, Shiboski CH, Criswell L, et al. American College of Rheumatology clas‐ sification criteria for Sjögren's syndrome: a data-driven, expert consensus approach

and Sjogren's syndrome. Am J Ophthalmology 1988;105:512–18.

cal and pathophysiologic aspects. Medicine (Baltimore) 2009; 88(5):284–293.

2013(2013). Article ID 160491. doi: 10.1155/2013/160491

in Dry Eyes. CLAO J. 1995;21(4):221–32.

view. Arq Bras Oftalmol. 2013;76(2):129–32.

doi: 10.1016/j.ajo.2008.06.003. Epub 2008 Jul 30.

thalmol. 2000;129(3):372–5.

2014;8(3):216–22.

2001;12(4):250–7.

Basel, Karger, 2007 (92):195–202.

5.

164 Advances in Common Eye Infections

Rheum. 2007;56(12):3989–94.


[46] Romero-Rangel T, Stavrou P, Cotter J, Rosenthal P, Baltatzis S, Foster CS. Gas-perme‐ able scleral contact lens therapy in ocular surface disease. Am J Ophthalmol. 2000;130(1):25–32.

[33] Yavuz S1, Asfuroğlu E, Bicakcigil M, Toker E. Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren's syndrome. Rheumatol Int.

[34] Rihl M1, Ulbricht K, Schmidt RE, Witte T. Treatment of sicca symptoms with hydroxy‐ chloroquine in patients with Sjogren's syndrome. Rheumatology (Oxford). 2009;48(7):

[35] Chen S, Liu Y, Shi G. Anti-CD20 antibody in primary Sjögren's syndrome manage‐

[36] St Clair EW, Levesque MC, Prak ET, Vivino FB, Alappatt CJ, Spychala ME, Wedgwood J, McNamara J, Moser Sivils KL, Fisher L, Cohen P. Autoimmunity Centers of Excel‐ lence.Rituximabtherapy for primarySjögren's syndrome:anopen-labelclinicaltrialand mechanistic analysis. Arthritis Rheum. 2013;65(4):1097–106. doi: 10.1002/art.37850.

[37] Vossenkämper A, Lutalo PM, Spencer J Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjögren's syndrome: clinical implications and effects of B cell-targeted therapies. Clin Exp

[38] Steinfeld SD, Tant L, Burmester GR et al. Epratuzumab (humanised anti-CD22 anti‐ body) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res

[39] Xu J, Wang D, Liu D, Fan Z, et al. Allogeneic mesenchymal stem cell treatment allevi‐ ates experimental and clinical Sjögren syndrome. Blood 2012;120(15):3142–51.

[40] Sarkar J, Chaudhary, Namavari A, et al. Corneal neurotoxicity due to topical benzal‐

[41] Stephenson M. OTC Drops: Telling the Tears Apart. When choosing an over-thecounter artificial tear for your dry-eye patient, consider severity of disease and form of dry eye. Rev Ophtalmol. 2012; 19 (10):31-37. www.reviewofophthalmology.com/

[42] Keating GM. Diquafosol ophthalmic solution 3 %: a review of its use in dry eye.

[43] Ueda K, Matsumiya W, Otsuka K, Maeda Y, Nagai T, Nakamura M. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye.

[44] Kwiatkowska B, Maslinska M, Przygodzka M, Dmowska-Chalaba J, Dabrowska J, Si‐ korska-Siudek K. Immune system as a new therapeutic target for antibiotics. Adv Bi‐

[45] Bacon AS, Astin C, Dart JK. Silicone rubber contact lenses for the compromised cor‐

konium chloride. Invest Ophthalmol Vis Sci. 2012;53(4):1792–802.

Drugs. 2015;75(8):911–22. doi: 10.1007/s40265-015-0409-7.

BMC Ophthalmol. 2015;15:58. doi: 10.1186/s12886-015-0040-0.

2011;31(8):1045–9. doi: 10.1007/s00296-010-1415-4. Epub 2010 Mar 23.

796–9. doi: 10.1093/rheumatology/kep104. Epub 2009 May 11.

ment. Curr Pharm Biotechnol. 2014;15(6):535–41.

Immunol. 2012; 167(1):7–14.

Ther. 2006;8(4):R129.

166 Advances in Common Eye Infections

content/i/2133/c/36940/

osci Biotechnol. 2013;4:91–101.

nea. Cornea. 1994;13(5):422–8.

[47] Geerling G, Raus P, Murube J. Minor salivary gland transplantation. Dev Ophthal‐ mol. 2008;41:243–54. doi: 10.1159/000131093.
